Until the relationship between symptoms, lung function tests, airway inflammation, airway hyper-responsiveness (AHR), exacerbations and remodelling is clarified, regular treatment seems to enable a greater disease control than on-demand therapy in most patients with mild persistent asthma. Current guideline classification based on disease severity remains a cornerstone in asthma management. However, the heterogeneity of asthma, the growing emphasis on subphenotypes, including molecular phenotypes identified by -omics technologies, and their possible implications in terms of different asthma severity, progression and therapeutic response, are changing current asthma treatment mainly based on disease severity classification to a pharmacological strategy more focused on the individual patient.

Montuschi, P., Barnes, P., New perspectives in pharmacological treatment of mild persistent asthma, <<DRUG DISCOVERY TODAY>>, 2011; 16 (23-24): 1084-1091. [doi:10.1016/j.drudis.2011.09.005] [http://hdl.handle.net/10807/4236]

New perspectives in pharmacological treatment of mild persistent asthma

Montuschi, Paolo;
2011

Abstract

Until the relationship between symptoms, lung function tests, airway inflammation, airway hyper-responsiveness (AHR), exacerbations and remodelling is clarified, regular treatment seems to enable a greater disease control than on-demand therapy in most patients with mild persistent asthma. Current guideline classification based on disease severity remains a cornerstone in asthma management. However, the heterogeneity of asthma, the growing emphasis on subphenotypes, including molecular phenotypes identified by -omics technologies, and their possible implications in terms of different asthma severity, progression and therapeutic response, are changing current asthma treatment mainly based on disease severity classification to a pharmacological strategy more focused on the individual patient.
2011
Inglese
Montuschi, P., Barnes, P., New perspectives in pharmacological treatment of mild persistent asthma, <<DRUG DISCOVERY TODAY>>, 2011; 16 (23-24): 1084-1091. [doi:10.1016/j.drudis.2011.09.005] [http://hdl.handle.net/10807/4236]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/4236
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact